Research programme: anti-cancer therapeutics- Bionetix/ Southern Research

Drug Profile

Research programme: anti-cancer therapeutics- Bionetix/ Southern Research

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionetix; Southern Research Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Oct 2017 Early research in Cancer in South Korea, USA (unspecified route)
  • 02 Oct 2017 Southern Research and Bionetix agree to co-develop anti-cancer drugs in USA for Cancer
  • 02 Oct 2017 Southern Research in collaboration with Bionetix plans preclinical and clinical studies for Cancer in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top